Currently patients with glioblastoma have a median survival of approximately 14.6 months and 5-year survival rates below 5%.

Voranigo plus Temodar was safe in glioma with IDH1/2 mutations. Among patents with IDH1- or IDH2-mutant glioma, the treatment ...

Gomekli showed an 87% overall response rate in pediatric low-grade glioma with MAPK pathway activation, with a recommended ...

Early data indicate Voranigo (vorasidenib) is being rapidly adopted in patients with isocitrate dehydrogenase–mutated glioma, ...

Recent real-world study findings have identified a potential unmet need for an effective early treatment with minimal ...

Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive ...

The lidERA Breast Cancer study is a phase 3, randomized, open-label trial testing whether the adjuvant therapy giredestrant ...

Baker, a patient and patient advocate based in the United Kingdom, received a diagnosis of essential thrombocythemia (ET) in ...

GISTs are solid tumors, primarily in the stomach, characterized by KIT and EGFR mutations, with Gleevec as a key treatment.

Compassionate nursing care significantly impacts the emotional well-being of patients and their families during cancer treatment. Nurses' ability to engage in normal conversations provides a sense of ...

Nona Baker received a diagnosis of essential thrombocythemia in 1991, followed by polycythemia vera in 2004. It’s been nearly ...

Immune-based therapies are transforming advanced liver cancer care, resulting in curative options previously considered ...